Global Non-Surgical Rejuvenation Market Trends and Insights
Preference for Low-Downtime, Office-Based Treatments
Office-based care has become a central part of the non-surgical rejuvenation market because patients can fit treatment into normal work and family schedules. Minimally invasive procedures represented 80.00% of treatments among Gen X and Millennial facial rejuvenation seekers in 2025.Neurotoxin and filler appointments can often be completed within a short visit, which reduces the practical barrier associated with surgery. The appeal is strongest when patients can resume normal activity with limited recovery requirements. Product suppliers are therefore under pressure to demonstrate reliable outcomes and treatment intervals that support retention. In the United States, the FDA requirement that injectables be prescription products strengthens the distinction between compliant providers and informal sellers.Aging Population and Preventive Aesthetics
Population aging continues to support the non-surgical rejuvenation market, particularly for treatments addressing facial volume, skin texture, and laxity. The 40 to 54 age group held 42.34% of revenue in 2026, confirming its role as the established treatment base. Younger adults are also starting maintenance treatments earlier, which can lengthen the period over which they return for care. A 2025 Pew Research Center survey found that 23.00% of U.S. adults had received or would consider non-surgical treatments such as botulinum toxin or dermal fillers.Patients aged 55 to 69 and those aged 70 and above add further demand as acceptance of aesthetic treatment expands. This broadening age range supports combination treatment plans rather than a single, occasional procedure.Counterfeit and Gray-Market Injectables
Counterfeit and gray-market injectables remain a serious safety and trust issue for the non-surgical rejuvenation market. UK authorities recorded 41 confirmed botulism cases between June and August 2025 that were linked to unlicensed botulinum toxin products. The MHRA response targeted sellers using social media and unlicensed practitioners operating in informal settings. New York City also issued a 2025 health advisory on severe illness linked to self-injection of botulinum toxin products obtained from unlicensed sources. Such events can make price-sensitive consumers hesitant about treatment even when they are considering a legitimate provider. Providers and manufacturers need product authentication, patient education, and disciplined purchasing controls to protect confidence in the category.Other drivers and restraints analyzed in the detailed report include:
- Social Media, Video Calls, and Appearance Awareness
- Expansion of Medical Spas and Tier-Two Access
- Competing Weight-Loss Pharmacotherapy Reducing Fat-Reduction Demand
Segment Analysis
Injectable neurotoxins held 34.72% of the non-surgical rejuvenation market share in 2026, making them the largest product category. Their large installed patient base reflects repeated treatment cycles and broad use across preventive and corrective facial care. In the United States, 9.90 million neuromodulator injections were performed in 2024, up 4.00% from the prior year.Topical and skin booster products are forecast to grow at a 10.21% CAGR from 2027 to 2032, the fastest rate among product types. Their growth reflects clinician interest in polynucleotides, PDRN, and skin-booster hyaluronic acid across facial and body protocols. These products are often used with injectables or energy-based procedures rather than as complete substitutes. That clinical role can raise the value of a treatment visit when providers select products around hydration, texture, and tissue quality. Energy-based systems remain relevant across laser, intense pulsed light, radiofrequency, high-intensity focused ultrasound, cryolipolysis, and electromagnetic muscle stimulation.
Facial aesthetics accounted for 66.26% of the non-surgical rejuvenation market share in 2026. Its size reflects a broad set of needs involving expression lines, volume loss, skin quality, and visible age-related change. Neuromodulators and fillers remain central because they can be adapted to preventive treatment and later-stage correction. Facial treatment also benefits from combination protocols that incorporate energy-based devices within a single care plan.
Hair and scalp treatments are forecast to grow at a 7.74% CAGR from 2027 to 2032, the fastest rate across treatment areas. Rising awareness of androgenetic alopecia is bringing more patients into non-surgical hair solutions. Platelet-rich plasma and injectable scalp biostimulators are becoming part of the treatment discussion for patients seeking earlier intervention. Male patients provide an important source of demand because hair and facial treatments can be considered together. Body contouring and fat reduction face a changing demand mix as GLP-1 use reshapes patient preferences. Patients with post-weight-loss laxity may favor radiofrequency or high-intensity focused ultrasound over treatments directed only at fat removal.
Complete Report Scope:
- By Product Type
- Injectable Neurotoxins
- Botulinum Toxin Type A
- Botulinum Toxin Type B
- Injectable Dermal Fillers
- Hyaluronic Acid
- Calcium Hydroxylapatite
- Poly-L-Lactic Acid
- Collagen and PMMA Microspheres
- Others
- Energy-Based Systems
- Laser and IPL Platforms
- Radiofrequency Devices
- Ultrasound and HIFU Platforms
- Cryolipolysis Systems
- Electromagnetic Muscle Stimulators
- Topical and Skin Booster Products
- Injectable Neurotoxins
- By Treatment Area
- Facial Aesthetics
- Body Contouring and Fat Reduction
- Skin Rejuvenation, Pigment, and Texture
- Hair and Scalp Treatments
- Other Treatment Areas
- By Gender
- Female
- Male
- By Age Group
- 13-39 Years
- 40-54 Years
- 55-69 Years
- 70+ Years
- By End User
- Dermatology and Plastic-Surgery Clinics
- Medical Spas
- Hospitals and Ambulatory Centers
- Traditional Spas
- Other End Users
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America accounted for 41.32% of the non-surgical rejuvenation market share in 2026. The region has high injectable procedure volumes, established consumer awareness, and a dense provider base. In the United States, 9.88 million botulinum toxin procedures and 5.33 million hyaluronic acid filler procedures were recorded in 2024. Six FDA-approved neuromodulators compete in the country, and Hugel fully commercialized Letybo in the United States in March 2025.Asia-Pacific is forecast to grow at a 9.35% CAGR from 2027 to 2032, the highest regional rate. Growth is supported by expanding clinic networks, rising incomes, and broadening acceptance of routine aesthetic maintenance. South Korea remains an innovation center for neuromodulators and aesthetic protocols. Korean brands and treatment approaches are increasingly reaching China, Southeast Asia, and Western markets. SoYoung reported that light-aesthetic clinic chain revenue grew 426.00% year over year in the second quarter of 2025.
Europe is a mature region with deep adoption of injectables and energy-based systems across Germany, the United Kingdom, France, Italy, and Spain. The EU Medical Device Regulation has raised approval and compliance standards for device suppliers, supporting established manufacturers with proven quality systems. Swissmedic approved Ipsen's Relfydess in March 2025 for glabellar and lateral canthal lines in adults under 65, increasing neuromodulator choice in Switzerland.
List of Companies Covered in this Report:
- Abbvie
- Alma Lasers
- BTL INDUSTRIES Inc.
- Candela Medical
- Cutera
- Cynosure LLC
- Daewoong Pharmaceutical Co., Ltd
- Evolus Inc.
- Fotona d.o.o.
- Galderma
- Hugel Inc.
- InMode Ltd
- Jeisys Medical Inc.
- Lumenis
- Lutronic
- Merz Pharma GmbH and Co. KGaA
- Revance Therapeutics
- Sciton
- Sinclair Pharma Limited
- Solta Medical
- Teoxane SA
- Venus Concept Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Alma Lasers Ltd
- BTL INDUSTRIES Inc.
- Candela Corporation
- Cutera Inc.
- Cynosure LLC
- Daewoong Pharmaceutical Co., Ltd
- Evolus Inc.
- Fotona d.o.o.
- Galderma SA
- Hugel Inc.
- InMode Ltd
- Jeisys Medical Inc.
- Lumenis Be Ltd
- Lutronic Corporation
- Merz Pharma GmbH and Co. KGaA
- Revance Therapeutics Inc.
- Sciton Inc.
- Sinclair Pharma Limited
- Solta Medical
- Teoxane SA
- Venus Concept Inc.

